Axsome Historical Balance Sheet

AXSM Stock

USD 119.16 1.20 1.00%

Trend analysis of Axsome Therapeutics balance sheet accounts such as Short Long Term Debt Total of 201.1 M, Other Current Liabilities of 163.1 M or Total Current Liabilities of 241.6 M provides information on Axsome Therapeutics' total assets, liabilities, and equity, which is the actual value of Axsome Therapeutics to its prevalent stockholders. By breaking down trends over time using Axsome Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Axsome Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Axsome Therapeutics is a good buy for the upcoming year.

Axsome Therapeutics Inventory

16.52 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

About Axsome Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Axsome Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Axsome Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Axsome Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Axsome currently owns. An asset can also be divided into two categories, current and non-current.

Axsome Therapeutics Balance Sheet Chart

At this time, Axsome Therapeutics' Cash is very stable compared to the past year. As of the 27th of March 2025, Cash And Short Term Investments is likely to grow to about 331.1 M, though Retained Earnings are likely to grow to (1.1 B).

Short Long Term Debt Total Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Axsome Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Axsome Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Axsome Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Axsome Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Axsome Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Cash is very stable compared to the past year. As of the 27th of March 2025, Cash And Short Term Investments is likely to grow to about 331.1 M, though Retained Earnings are likely to grow to (1.1 B).

	2022	2023	2024	2025 (projected)
Other Current Liabilities	57.5M	96.9M	155.3M	163.1M
Short and Long Term Debt Total	94.7M	186.4M	191.5M	201.1M

Other Current Liab Short Long Term Debt Total

Axsome Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Non Current Liabilities Total
Total Assets		0.86	0.86	0.86	0.63	-0.74	-0.81	0.85	0.87	0.87	0.48	0.6	0.88	0.81	0.87	0.91	-0.18	0.63	0.45	0.38	0.62	0.87	0.85	0.54	0.85	0.87
Short Long Term Debt Total	0.86		0.97	0.97	0.41	-0.68	-0.98	0.96	0.92	0.92	0.62	0.76	0.95	0.99	0.99	0.97	-0.32	0.76	0.54	0.21	0.78	0.93	0.93	0.07	1.0	1.0
Other Current Liab	0.86	0.97		1.0	0.47	-0.55	-0.96	0.98	0.84	0.84	0.5	0.65	0.99	0.95	0.99	0.92	-0.24	0.66	0.48	0.14	0.69	0.92	0.96	0.15	0.96	0.98
Total Current Liabilities	0.86	0.97	1.0		0.44	-0.59	-0.97	0.99	0.86	0.86	0.54	0.68	0.99	0.95	0.99	0.93	-0.24	0.69	0.51	0.19	0.73	0.92	0.97	0.15	0.96	0.98
Total Stockholder Equity	0.63	0.41	0.47	0.44		-0.1	-0.31	0.38	0.28	0.28	-0.21	-0.05	0.53	0.34	0.45	0.37	0.05	-0.01	-0.16	-0.28	-0.11	0.6	0.53	0.69	0.41	0.46
Net Debt	-0.74	-0.68	-0.55	-0.59	-0.1		0.66	-0.62	-0.91	-0.91	-0.77	-0.8	-0.55	-0.64	-0.63	-0.82	0.33	-0.8	-0.64	-0.81	-0.85	-0.61	-0.54	-0.13	-0.68	-0.64
Retained Earnings	-0.81	-0.98	-0.96	-0.97	-0.31	0.66		-0.98	-0.91	-0.91	-0.69	-0.82	-0.95	-0.99	-0.98	-0.95	0.33	-0.82	-0.6	-0.24	-0.84	-0.92	-0.94	0.02	-0.98	-0.98
Accounts Payable	0.85	0.96	0.98	0.99	0.38	-0.62	-0.98		0.87	0.87	0.61	0.73	0.97	0.96	0.98	0.94	-0.3	0.74	0.56	0.25	0.79	0.92	0.97	0.1	0.96	0.97
Cash	0.87	0.92	0.84	0.86	0.28	-0.91	-0.91	0.87		1.0	0.75	0.85	0.83	0.9	0.89	0.98	-0.35	0.85	0.64	0.55	0.89	0.85	0.81	0.11	0.92	0.9
Cash And Short Term Investments	0.87	0.92	0.84	0.86	0.28	-0.91	-0.91	0.87	1.0		0.75	0.85	0.83	0.9	0.89	0.98	-0.35	0.85	0.64	0.55	0.89	0.85	0.81	0.11	0.92	0.9
Common Stock Total Equity	0.48	0.62	0.5	0.54	-0.21	-0.77	-0.69	0.61	0.75	0.75		0.95	0.51	0.64	0.57	0.69	-0.43	0.97	0.86	0.59	0.91	0.54	0.52	-0.23	0.62	0.57
Common Stock Shares Outstanding	0.6	0.76	0.65	0.68	-0.05	-0.8	-0.82	0.73	0.85	0.85	0.95		0.64	0.78	0.71	0.8	-0.35	0.98	0.74	0.49	0.93	0.7	0.66	-0.19	0.76	0.72
Other Current Assets	0.88	0.95	0.99	0.99	0.53	-0.55	-0.95	0.97	0.83	0.83	0.51	0.64		0.93	0.98	0.91	-0.26	0.67	0.52	0.13	0.67	0.93	0.97	0.22	0.95	0.97
Other Stockholder Equity	0.81	0.99	0.95	0.95	0.34	-0.64	-0.99	0.96	0.9	0.9	0.64	0.78	0.93		0.98	0.94	-0.36	0.77	0.54	0.19	0.81	0.93	0.94	-0.01	0.99	0.98
Total Liab	0.87	0.99	0.99	0.99	0.45	-0.63	-0.98	0.98	0.89	0.89	0.57	0.71	0.98	0.98		0.96	-0.27	0.72	0.51	0.19	0.75	0.93	0.96	0.12	0.99	1.0
Total Current Assets	0.91	0.97	0.92	0.93	0.37	-0.82	-0.95	0.94	0.98	0.98	0.69	0.8	0.91	0.94	0.96		-0.31	0.81	0.6	0.43	0.85	0.9	0.88	0.14	0.97	0.96
Short Term Debt	-0.18	-0.32	-0.24	-0.24	0.05	0.33	0.33	-0.3	-0.35	-0.35	-0.43	-0.35	-0.26	-0.36	-0.27	-0.31		-0.42	-0.5	-0.22	-0.43	-0.31	-0.28	0.22	-0.33	-0.29
Common Stock	0.63	0.76	0.66	0.69	-0.01	-0.8	-0.82	0.74	0.85	0.85	0.97	0.98	0.67	0.77	0.72	0.81	-0.42		0.82	0.51	0.91	0.7	0.67	-0.13	0.76	0.73
Other Liab	0.45	0.54	0.48	0.51	-0.16	-0.64	-0.6	0.56	0.64	0.64	0.86	0.74	0.52	0.54	0.51	0.6	-0.5	0.82		0.53	0.77	0.46	0.47	-0.13	0.53	0.51
Net Tangible Assets	0.38	0.21	0.14	0.19	-0.28	-0.81	-0.24	0.25	0.55	0.55	0.59	0.49	0.13	0.19	0.19	0.43	-0.22	0.51	0.53		0.63	0.12	0.13	0.11	0.21	0.18
Current Deferred Revenue	0.62	0.78	0.69	0.73	-0.11	-0.85	-0.84	0.79	0.89	0.89	0.91	0.93	0.67	0.81	0.75	0.85	-0.43	0.91	0.77	0.63		0.69	0.69	-0.21	0.79	0.74
Non Current Assets Total	0.87	0.93	0.92	0.92	0.6	-0.61	-0.92	0.92	0.85	0.85	0.54	0.7	0.93	0.93	0.93	0.9	-0.31	0.7	0.46	0.12	0.69		0.97	0.2	0.94	0.94
Non Currrent Assets Other	0.85	0.93	0.96	0.97	0.53	-0.54	-0.94	0.97	0.81	0.81	0.52	0.66	0.97	0.94	0.96	0.88	-0.28	0.67	0.47	0.13	0.69	0.97		0.19	0.93	0.94
Other Assets	0.54	0.07	0.15	0.15	0.69	-0.13	0.02	0.1	0.11	0.11	-0.23	-0.19	0.22	-0.01	0.12	0.14	0.22	-0.13	-0.13	0.11	-0.21	0.2	0.19		0.06	0.11
Long Term Debt	0.85	1.0	0.96	0.96	0.41	-0.68	-0.98	0.96	0.92	0.92	0.62	0.76	0.95	0.99	0.99	0.97	-0.33	0.76	0.53	0.21	0.79	0.94	0.93	0.06		1.0
Non Current Liabilities Total	0.87	1.0	0.98	0.98	0.46	-0.64	-0.98	0.97	0.9	0.9	0.57	0.72	0.97	0.98	1.0	0.96	-0.29	0.73	0.51	0.18	0.74	0.94	0.94	0.11	1.0

Click cells to compare fundamentals

Axsome Therapeutics Account Relationship Matchups

Axsome Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	186.1M	(338.4M)	331.5M	588.2M	568.5M	596.9M
Short Long Term Debt Total	50.1M	49.7M	94.7M	186.4M	191.5M	201.1M
Other Current Liab	8.7M	9.3M	57.5M	96.9M	155.3M	163.1M
Total Current Liabilities	23.4M	23.1M	96.6M	138.9M	230.1M	241.6M
Total Stockholder Equity	(278.8M)	(409.2M)	109.6M	191.0M	57.0M	59.9M
Net Debt	(133.8M)	(36.8M)	(106.2M)	(199.8M)	(123.8M)	(117.6M)
Retained Earnings	(278.8M)	(409.2M)	(596.3M)	(835.6M)	(1.1B)	(1.1B)
Accounts Payable	13.5M	13.1M	38.6M	40.7M	72.0M	75.6M
Cash	183.9M	86.5M	200.8M	386.2M	315.4M	331.1M
Cash And Short Term Investments	183.9M	86.5M	200.8M	386.2M	315.4M	331.1M
Common Stock Total Equity	3.0K	3.7K	3.7K	3.8K	4.3K	2.7K
Common Stock Shares Outstanding	37.2M	37.6M	40.7M	45.4M	47.9M	32.0M
Liabilities And Stockholders Equity	(206.5M)	(338.4M)	331.5M	588.2M	568.5M	596.9M
Other Current Assets	148.4K	45.3K	5.6M	8.1M	12.0M	12.6M
Other Stockholder Equity	392.6M	424.8M	705.9M	1.0B	1.2B	1.2B
Total Liab	72.3M	70.8M	221.9M	397.3M	511.5M	537.1M
Total Current Assets	184.0M	86.5M	245.6M	504.3M	485.1M	509.3M
Short Term Debt	1.2M	620.7K	425K	1.3M	1.8M	1.4M
Common Stock	3.7K	3.8K	4.4K	5K	5.8K	3.4K
Net Tangible Assets	178.7M	113.8M	15.6M	39.6M	45.5M	52.6M
Non Current Assets Total	2.1M	1.3M	85.8M	84.0M	83.4M	87.6M
Non Currrent Assets Other	317.4K	322.9K	14.7M	11.0M	19.1M	20.1M
Other Assets	139.9K	2.1M	(426.1M)	14.7M	13.2M	13.9M
Long Term Debt	48.3M	49.1M	94.3M	178.1M	180.7M	189.7M
Non Current Liabilities Total	48.9M	49.1M	125.4M	258.4M	281.4M	295.4M
Property Plant And Equipment Net	1.8M	944.0K	1.1M	7.6M	5.4M	5.7M
Property Plant And Equipment Gross	1.8M	944.0K	1.1M	7.6M	6.0M	6.3M
Property Plant Equipment	30.6K	52.6K	283.8K	1.1M	1.3M	1.4M
Retained Earnings Total Equity	(107.6M)	(175.9M)	(278.8M)	(409.2M)	(368.3M)	(349.9M)
Long Term Debt Total	3.6M	17.3M	48.3M	49.1M	56.5M	59.3M
Capital Surpluse	108.5M	354.6M	392.6M	424.8M	488.5M	264.6M
Net Invested Capital	162.1M	64.7M	203.8M	369.0M	237.7M	174.7M
Net Working Capital	160.6M	63.5M	149.1M	365.4M	255.0M	167.3M
Capital Stock	3.7K	3.8K	4.4K	5K	5.8K	4.5K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:

How To Invest In Axsome

Details

Is Axsome Stock a good investment?

Details

What is Axsome Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.99)

Revenue Per Share

8.05

Quarterly Revenue Growth

0.66

Return On Assets

(0.27)

Return On Equity

(2.32)

The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Axsome Historical Balance Sheet

Axsome Therapeutics Inventory

16.52 Million

About Axsome Balance Sheet Analysis

Axsome Therapeutics Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Axsome Therapeutics balance sheet Correlations

Axsome Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Axsome Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 1.0	Total Liab
Non Current Liabilities Total	+ 1.0	Long Term Debt

Other Stockholder Equity	- 0.99	Retained Earnings
Non Current Liabilities Total	- 0.98	Retained Earnings
Long Term Debt	- 0.98	Retained Earnings
Total Liab	- 0.98	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Short Long Term Debt Total